Registry for Hypertrophic Cardiomyopathy in Taiwan
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
This study is trying to gather information about hypertrophic cardiomyopathy and related diseases in adults in Taiwan to improve how they are diagnosed and treated.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2600 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Far Eastern Memorial Hospital Academic / other |
| Locations | 1 site (New Taipei City) |
| Trial ID | NCT06381778 on ClinicalTrials.gov |
What this trial studies
This registry aims to evaluate the clinical, genetic, and biochemical features of hypertrophic cardiomyopathy (HCM) and related rare diseases like Fabry disease in Taiwan. It will systematically assess the prevalence of HCM within the Taiwanese population and identify specific 'red-flag' signs for Fabry disease. The study will include adult patients with left ventricular hypertrophy (LVH) and will gather data through echocardiograms and cardiac MRI. The goal is to improve diagnosis and treatment strategies for HCM and related conditions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older with left ventricular hypertrophy as determined by echocardiogram or cardiac MRI.
Not a fit: Patients with conditions like co-arctation of the aorta or severe aortic stenosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to better diagnosis and management of hypertrophic cardiomyopathy and related rare diseases in patients.
How similar studies have performed: Other studies have shown success in characterizing hypertrophic cardiomyopathy, but this specific registry approach focusing on the Taiwanese population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Presence of left ventricular hypertrophy (LVH) on echo/CMRI: 2. maximal interventricular septal (IVST) and/or posterior wall thickness (PWT) ≥13 mm, 3. apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR 4. maximal LV wall thickness ≥ 15mm of ANY OTHER PART 5. Male and female adult age ≥ 20 year-old 6. Patients willing to comply with and sign the informed consent Exclusion Criteria: 1. Patients refuse or unable to give informed consent 2. Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program 3. Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload 4. Athletic heart 5. Non-compaction cardiomyopathy
Where this trial is running
New Taipei City
- Far Eastern Memorial Hospital — New Taipei City, Taiwan (Recruiting)
Study contacts
- Study coordinator: Yen-Wen Wu, PhD
- Email: wuyw0502@gmail.com
- Phone: +886289667000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.